NRGN and Alzheimer disease: However, the observed cortical and hippocampal levels of ZnT3, Dyn1 or GluA3 in the App knock-in models are highly comparable to previous observations of the synaptic profile of Alzheimer’s disease patients presenting along with the robust decrease in neurogranin, PSD95 or GluA3 levels region dependent changes in ZnT3 and Dyn1 levels.19,21,44